BACKGROUND: After external beam radiation therapy (EBRT) for prostate cancer, a short interval to biochemical failure of <18 months has been proposed as a surrogate for cause-specific survival. Because EBRT dose influences biochemical failure, the authors investigated the interval to biochemical failure in a cohort of patients treated with dose-escalated EBRT. METHODS: From 1998 to 2008, 710 patients were treated with EBRT (≥75 grays) ± androgen deprivation therapy (ADT) at the University of Michigan. Biochemical failure was defined using the Phoenix consensus definition (nadir + 2 ng/mL). A short interval to biochemical failure was defined as <18 months after completing radiotherapy and/or ADT. The associations between biochemical failure, the interval to biochemical failure, and clinical factors with cause-specific survival (CSS) and overall survival (OS) were evaluated. RESULTS: There were 149 biochemical failures (21%), and short interval to biochemical failure accounted for 14% and 40% of biochemical failures in those with intermediate-risk or high-risk disease, respectively. Biochemical failure impacted CSS (P < .0001) but not OS (P = .36). However, a short interval to biochemical failure predicted decreased CSS (P < .0001; hazard ratio [HR], 5.6; 95% confidence interval [CI], 2.4-13.0) and OS (P < .0001; HR, 4.8; 95% CI, 2.3-10.3) when compared with a long interval to biochemical failure. The 8-year OS was 78% without biochemical failure, compared with 87% with a long interval to biochemical failure (P = .1; HR, 0.7; 95% CI, 0.4-1.1) and 38% with a short interval to biochemical failure (P < .0001; HR, 3.7; 95% CI, 2.3-5.9). On multivariate analysis, a short interval to biochemical failure increased the risk of prostate cancer death (P < .0001; HR, 18.1; 95% CI, 8.4-39) and all cause mortality (P = .0027; HR, 1.5; 95% CI, 1.2-2.1), whereas a long interval to biochemical failure did not. CONCLUSIONS: The relation between the interval to biochemical failure, CSS, and OS was independently validated in patients treated with dose-escalated EBRT. Further evaluation of the interval to biochemical failure as a surrogate endpoint is warranted.
BACKGROUND: After external beam radiation therapy (EBRT) for prostate cancer, a short interval to biochemical failure of <18 months has been proposed as a surrogate for cause-specific survival. Because EBRT dose influences biochemical failure, the authors investigated the interval to biochemical failure in a cohort of patients treated with dose-escalated EBRT. METHODS: From 1998 to 2008, 710 patients were treated with EBRT (≥75 grays) ± androgen deprivation therapy (ADT) at the University of Michigan. Biochemical failure was defined using the Phoenix consensus definition (nadir + 2 ng/mL). A short interval to biochemical failure was defined as <18 months after completing radiotherapy and/or ADT. The associations between biochemical failure, the interval to biochemical failure, and clinical factors with cause-specific survival (CSS) and overall survival (OS) were evaluated. RESULTS: There were 149 biochemical failures (21%), and short interval to biochemical failure accounted for 14% and 40% of biochemical failures in those with intermediate-risk or high-risk disease, respectively. Biochemical failure impacted CSS (P < .0001) but not OS (P = .36). However, a short interval to biochemical failure predicted decreased CSS (P < .0001; hazard ratio [HR], 5.6; 95% confidence interval [CI], 2.4-13.0) and OS (P < .0001; HR, 4.8; 95% CI, 2.3-10.3) when compared with a long interval to biochemical failure. The 8-year OS was 78% without biochemical failure, compared with 87% with a long interval to biochemical failure (P = .1; HR, 0.7; 95% CI, 0.4-1.1) and 38% with a short interval to biochemical failure (P < .0001; HR, 3.7; 95% CI, 2.3-5.9). On multivariate analysis, a short interval to biochemical failure increased the risk of prostate cancer death (P < .0001; HR, 18.1; 95% CI, 8.4-39) and all cause mortality (P = .0027; HR, 1.5; 95% CI, 1.2-2.1), whereas a long interval to biochemical failure did not. CONCLUSIONS: The relation between the interval to biochemical failure, CSS, and OS was independently validated in patients treated with dose-escalated EBRT. Further evaluation of the interval to biochemical failure as a surrogate endpoint is warranted.
Authors: James J Dignam; Daniel A Hamstra; Herbert Lepor; David Grignon; Harmar Brereton; Adam Currey; Seth Rosenthal; Kenneth L Zeitzer; Varagur M Venkatesan; Eric M Horwitz; Thomas M Pisansky; Howard M Sandler Journal: J Clin Oncol Date: 2018-12-07 Impact factor: 44.544
Authors: Daniel A Hamstra; Kyounghwa Bae; Gerald Hanks; Chen Hu; William U Shipley; Charlie C Pan; Mack Roach; Colleen A Lawton; Howard M Sandler Journal: Cancer Date: 2014-11-19 Impact factor: 6.860
Authors: Katharina Beyer; Vera Straten; Sebastiaan Remmers; Steven MacLennan; Sara MacLennan; Giorgio Gandaglia; Peter-Paul M Willemse; Ronald Herrera; Muhammad Imran Omar; Beth Russell; Johannes Huber; Markus Kreuz; Alex Asiimwe; Tom Abbott; Alberto Briganti; Mieke Van Hemelrijck; Monique J Roobol Journal: J Pers Med Date: 2022-05-05
Authors: Carlos Antônio da Silva Franca; Sérgio Lannes Vieira; Antonio Carlos Pires Carvalho; Antonio Jose Serrano Bernabe; Antonio Belmiro Rodrigues Campbell Penna Journal: Radiol Bras Date: 2014 Mar-Apr
Authors: Al V Taira; Gregory S Merrick; Wayne M Butler; Robert W Galbreath; Ryan Fiano; Kent E Wallner; Edward Adamovich Journal: J Contemp Brachytherapy Date: 2013-12-03